This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
From September 29 to October 1, 2025, groninger will showcase its latest innovations at PACK EXPO Las Vegas, addressing the evolving challenges of the pharmaceutical industry. At Booth N-6000, the company will present its cutting-edge machine concepts, flexfill and robocell, which combine precision, safety, and flexibility in liquid pharmaceutical processing.
When the global packaging and pharmaceutical industries gather at PACK EXPO Las Vegas 2025, the focus will not only be on trends and technologies—but on real solutions for tomorrow’s challenges. As one of the leading trade shows in the U.S., PACK EXPO provides a stage for innovations that are shaping the industry. groninger will use this platform to present two machine concepts that redefine pharmaceutical production.
“Our customers face complex regulatory, technological, and logistical challenges every day. As specialists in filling and closing systems, we understand these demands—and develop solutions that are not only technically advanced but also practical in daily operations,” says Jens Groninger, CEO of the groninger Group.
In pharmaceutical production, machine availability, time, flexibility, and safety are more critical than ever. “Manufacturers and CDMOs are under increasing pressure to deliver faster, safer, and more flexibly. These expectations are passed on to us as machine builders.”
flexfill: Fast Delivery, Modular Design, High Output
groninger will present the flexfill system virtually at PACK EXPO 2025. Designed for medium production volumes, the machine can process up to 12,000 RTU syringes, vials, or cartridges per hour. Thanks to preconfigured modules and a standardized, validated machine concept, the line can be delivered and commissioned in just eight months—cutting time to first batch by 50%.
The company is already working on the next generation: the flexfill400, which will handle up to 24,000 RTU units per hour while maintaining the proven advantages of the current flexfill line—modular configuration, standardized components, and fast delivery. First deliveries in this performance class are planned for 2027.
“Our flexfill is a promise to the industry: high adaptability within a standardized modular system, combined with maximum precision,” confirms Christian Thieme, VP of Sales & Marketing at groninger USA.
He and his team will be available on-site to engage with customers and partners. “Our solutions are not only technologically advanced, they also reflect our deep understanding of our customers’ challenges,” Thieme adds.
groninger robocell gloveless filling linegroninger
robocell: Gloveless Filling for Maximum Safety
This also applies to the robocell, groninger’s most innovative machine concept to date. “robocell is a completely gloveless filling system. Operators are entirely removed from critical process steps,” explains Thieme. The result is maximum safety for both operators and patients.
robocell is designed to process synthetic and biological drugs, as well as cell and gene therapies, ideal for small and micro-batch production. “We’re responding to a key trend in the pharmaceutical industry - personalized medicine instead of blockbuster production.”
Strategic Focus on the U.S. Market
“There’s a reason we’re presenting our latest machine concepts in Las Vegas. The U.S. remains the most important pharmaceutical market in the world,” emphasizes Jens Groninger.
This aligns with groninger’s current investments in its U.S. operations: The company is building a new headquarters in Charlotte, North Carolina, with an investment of approximately $14.2 million. The new facility will span 5,000 square meters and create 60 new jobs near the current site. The goal is to strengthen customer proximity, expand production capacity, and increase responsiveness to market demands.
“Our presence at PACK EXPO is much more than a trade show appearance. It’s part of our strategic expansion and a clear commitment to innovation, both in the U.S. and around the world.”
